×

HLA G-modified cells and methods

  • US 9,714,280 B2
  • Filed: 01/28/2015
  • Issued: 07/25/2017
  • Est. Priority Date: 07/31/2012
  • Status: Active Grant
First Claim
Patent Images

1. A genetically modified mammalian cell that has reduced immunogenicity and/or improved immunosuppression as compared to the mammalian cell without said genetic modification, whereinthe genetically modified mammalian cell comprises in its genome an exogenous nucleic acid comprising:

  • (a) a nucleic acid sequence encoding a Human leukocyte antigen-G (HLA-G) protein comprising a full length amino acid sequence of SEQ ID NO;

    2 operably linked to an Elongation Factor-1 alpha (EF-1α

    ) promoter comprising the sequence of SEQ ID NO;

    6; and

    (b) a 3′

    untranslated region (UTR) comprising a full length nucleotide sequence of SEQ ID NO;

    3;

    whereinthe genetically modified mammalian cell is selected from the group consisting of embryonic stem cell, embryonic epidermal progenitors and human dermal fibroblast cells, and wherein the encoded HLA-G protein is expressed by the genetically modified mammalian cell for at least seven weeks.

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×